Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03034668
Other study ID # 16-1991
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2016
Est. completion date August 2018

Study information

Verified date September 2018
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Purpose: To evaluate the acute and chronic effects of a botanical supplement on strength, muscle function, and lean body mass

Participants: The acute phase will include 30 participants, and the chronic phase will include 84 participants. All participants must be healthy recreationally active males between the ages of 18 and 35 years.

Procedures (methods):

Acute phase: Participants will complete three testing visits as part of as part of a cross-over design, during which strength and muscle function will be assessed prior to and following consumption of a supplement. The experimental supplement is a blend of the botanical extracts; treatment arms will include a full dose (FULL; 350 mg capsule), half dose (HALF; 175 mg plus maltodextrin), or placebo (PLA; maltodextrin).

Chronic phase: Body composition, muscle cross-sectional area, a complete blood count and metabolic panel, subjective surveys, and strength will be measured prior to and following an 8-week supervised resistance training program, in conjunction with daily supplementation of FULL, HALF, or PLA.


Recruitment information / eligibility

Status Completed
Enrollment 119
Est. completion date August 2018
Est. primary completion date August 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria:

- Recreationally Active (1- 4 hours of exercise/ sports participation per week and no more than 1 hour of resistance training exercise per week) for the previous 12 weeks.

- BMI < 30 kg/m²

- Have not smoked in the past year.

- Participant has provided written and dated informed consent to participate in the study

- Participant is willing and able to comply with the protocol

- Participant is apparently healthy and free from disease, as determined by a health history questionnaire

- Participant agrees to abstain from caffeine, tobacco, alcohol, and exercise within 24 hours of testing visits

Exclusion Criteria:

- Participant has not used any dietary supplements within 12 weeks prior to enrollment and will not begin supplementation during the study. Potential supplements include but are not limited to Beta-alanine, Creatine, HMB, Carnosine, Taurine, androstenedione, DHEA, Whey protein, or a pre-workout supplement.

- Participant has gained or lost 10 lbs in the previous 2 months.

- Participant is currently enrolled in a separate clinical trial.

- Participant has participated in a clinical trial within the previous 2 months that includes modifications to their physical and/or diet.

- Participant has a known allergy or sensitivity to the placebo (maltodextrin) or active ingredients (Rhodiola & Rhaptonicum)

- Participant consumes more than 8 cups (1 cup = 6 oz) of coffee per day on a regular basis

- Participant consumes more than 3 alcoholic drinks per day.

- Participant uses recreational drugs daily.

- Previous physical symptoms causing a physician to recommend you to refrain from exercise.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
CS16-003 Full dose
350 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts
CS16-003 Half dose
175 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts + maltodextrin 175 mg
Placebo
Maltodextrin: 350 mg

Locations

Country Name City State
United States University of North Carolina, Department of Exercise and Sport Science Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill Naturex SA

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximal Isokinetic Leg Extension strength measured by dynamometry Acute/Immediate
Primary Maximal Upper and Lower Body Strength measured by 1 repetition maximum 8 weeks
Secondary Bench Press Repetitions to Fatigue 8 weeks
Secondary Leg Press Repetitions to Fatigue 8 weeks
Secondary Body Composition-Lean Mass 8 weeks
Secondary Body Composition-Fat Mass 8 weeks
Secondary Muscle cross sectional area 8 weeks
Secondary Change in Quality of Life Score from baseline to 8 weeks Quality of life from a visual analog scale (VAS) 0-100, with 0 = worst quality of life and 100=best quality of life. baseline, 8 weeks
Secondary Change in Felt Arousal score from baseline to 8 weeks Felt arousal scale. Scores range 1-6 with 1 being low arousal and 6 being high. One score selected. baseline, 8 weeks
Secondary Change in Mood score from baseline to 8 weeks Mood determined from a VAS. 0-100, with 0 = not depressed at all and 100 = most depressed. baseline; 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1